Paper I — Q8
What is enteric fever? What are its causative agents? Give a detailed presentation of a case according to the time of the disease…
What is enteric fever? What are its causative agents? Give a detailed presentation of a case according to the time of the disease and the respective tests used for diagnosis.
Draw a diagram of HIV virion depicting the various antigens and proteins. Give the serological pattern in an HIV infection according to the time of presentation. List the various diseases associated with AIDS.
What is virtual autopsy? State its methodology. What are its merits?
Define brain death. Describe its medicolegal importance.
Discuss why infliximab is considered as an immunosuppressant. Mention its therapeutic uses.
Describe briefly the pharmacological characteristics of natriuretic peptides and their clinical uses.
हिंदी में प्रश्न पढ़ें
आंत्र ज्वर क्या है? उसके कारक कौन-कौन से हैं? रोग की अवधि के अनुसार आंत्र ज्वर के मामले में किस समय पर क्या अभिव्यक्तियाँ होंगी और अलग-अलग समय पर कौन-कौन से टेस्ट निदान कर सकेंगे, इसका पूरा विवरण दीजिए।
HIV विरियन का चित्र बनाइए, जिसमें विभिन्न प्रतिजनों तथा प्रोटीनों को चिह्नित किया गया हो। एक HIV संक्रमण के मामले में अभिव्यक्ति की समयावधि के अनुसार सीरमी पैटर्न क्या होगा, लिखिए। AIDS से संबद्ध विभिन्न रोगों के नाम गिनाइए।
आभासी शव परीक्षण क्या है? उसकी विधि बताइए। उसकी अच्छाइयाँ क्या हैं?
मस्तिष्कीय मृत्यु (ब्रेन डेथ) को परिभाषित कीजिए। उसके चिकित्सा-विधिक महत्व का वर्णन कीजिए।
व्याख्या कीजिए कि इन्फ्लिक्सिमैब को इम्युनोसप्रेसेंट क्यों माना जाता है। उसके चिकित्सार्थ उपयोग को उल्लिखित कीजिए।
अतिसोडियममुक्त पेप्टाइडों की फार्माकोलॉजिकल विशेषताएँ तथा उनकी रोगलाक्षणिक उपयोगिताओं का संक्षेप में वर्णन कीजिए।
Model answer
Drafted with AI by UPSC Answer Check against this question's marking rubric, to the expected length. UPSC does not publish answers for Mains — this is one way to score well, not an official key. How we build rubrics and answers.
(a)(i) Enteric fever. Enteric fever is an acute systemic infection common in India, caused by Salmonella Typhi and S. Paratyphi A, B, C. After 1–2 weeks incubation, week 1 shows fever, headache, malaise and relative bradycardia; blood culture is positive (the best early test; bone-marrow culture is the most sensitive, even after antibiotics). Typhoid state and leucopenia may be present. Week 2 shows step-ladder fever, rose spots on trunk, hepatosplenomegaly; stool culture becomes positive. Week 3 may show intestinal haemorrhage or perforation; Widal test shows rising O and H titres, and urine culture may be positive. Week 4 is defervescence and recovery.
(a)(ii) HIV. Virion diagram: [envelope: gp120 surface spikes, gp41 transmembrane] → [matrix: p17] → [capsid: conical p24] → [core: two ssRNA, reverse transcriptase, integrase, protease, RNase H].
``svg <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 640 420" width="640" height="420"> <title>HIV virion</title> <defs><marker id="ar" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="7" markerHeight="7" orient="auto-start-reverse"><path d="M0,0 L10,5 L0,10 z" fill="#374151"/></marker></defs> <style>text{font-family:Arial,Helvetica,sans-serif;font-size:13px;fill:#1f2937}.t{font-size:15px;font-weight:bold}.b{font-weight:bold}.s{font-size:12px;fill:#4b5563}.c{text-anchor:middle}.e{text-anchor:end}.i{font-style:italic}</style> <rect width="640" height="420" fill="#fff"/> <text x="320" y="20" class="t c">HIV virion (schematic)</text> <circle cx="250" cy="220" r="135" fill="#fdf2f8" stroke="#374151" stroke-width="3"/> <circle cx="250" cy="220" r="122" fill="#fff7ed" stroke="#a16207" stroke-width="1.6" stroke-dasharray="6,4"/> <line x1="385" y1="220" x2="408" y2="220" stroke="#1f2937" stroke-width="3"/> <circle cx="415" cy="220" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="367" y1="288" x2="387" y2="299" stroke="#1f2937" stroke-width="3"/> <circle cx="393" cy="302" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="318" y1="337" x2="329" y2="357" stroke="#1f2937" stroke-width="3"/> <circle cx="332" cy="363" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="250" y1="355" x2="250" y2="378" stroke="#1f2937" stroke-width="3"/> <circle cx="250" cy="385" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="183" y1="337" x2="171" y2="357" stroke="#1f2937" stroke-width="3"/> <circle cx="168" cy="363" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="133" y1="288" x2="113" y2="299" stroke="#1f2937" stroke-width="3"/> <circle cx="107" cy="302" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="115" y1="220" x2="92" y2="220" stroke="#1f2937" stroke-width="3"/> <circle cx="85" cy="220" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="133" y1="153" x2="113" y2="141" stroke="#1f2937" stroke-width="3"/> <circle cx="107" cy="138" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="182" y1="103" x2="171" y2="83" stroke="#1f2937" stroke-width="3"/> <circle cx="167" cy="77" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="250" y1="85" x2="250" y2="62" stroke="#1f2937" stroke-width="3"/> <circle cx="250" cy="55" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="318" y1="103" x2="329" y2="83" stroke="#1f2937" stroke-width="3"/> <circle cx="332" cy="77" r="8" fill="#f9a8d4" stroke="#be185d"/> <line x1="367" y1="152" x2="387" y2="141" stroke="#1f2937" stroke-width="3"/> <circle cx="393" cy="137" r="8" fill="#f9a8d4" stroke="#be185d"/> <path d="M220,150 L280,150 L310,295 L190,295 Z" fill="#dbeafe" stroke="#1d4e78" stroke-width="2"/> <polyline points="230,170 233,176 235,182 236,188 235,194 234,200 231,206 228,212 225,218 224,224 224,230 226,236 228,242 231,248 234,254 236,260 236,266 235,272 232,278 230,284" fill="none" stroke="#b03030" stroke-width="2"/> <polyline points="265,170 266,176 265,182 264,188 261,194 258,200 255,206 254,212 254,218 256,224 258,230 261,236 264,242 266,248 266,254 265,260 262,266 260,272 257,278 255,284" fill="none" stroke="#b03030" stroke-width="2"/> <circle cx="220" cy="270" r="7" fill="#2e7d32"/> <circle cx="280" cy="268" r="7" fill="#7c3aed"/> <circle cx="250" cy="280" r="7" fill="#a16207"/> <line x1="400" y1="137" x2="430" y2="60" stroke="#6b7280" stroke-width="1"/> <text x="434" y="64" class="s" style="fill:#be185d">gp120 (surface glycoprotein)</text> <line x1="395" y1="220" x2="430" y2="110" stroke="#6b7280" stroke-width="1"/> <text x="434" y="114" class="s" style="fill:#1f2937">gp41 (transmembrane)</text> <line x1="346" y1="315" x2="430" y2="160" stroke="#6b7280" stroke-width="1"/> <text x="434" y="164" class="s" style="fill:#374151">lipid bilayer envelope</text> <line x1="362" y1="260" x2="430" y2="205" stroke="#6b7280" stroke-width="1"/> <text x="434" y="209" class="s" style="fill:#a16207">p17 matrix protein</text> <line x1="298" y1="250" x2="430" y2="250" stroke="#6b7280" stroke-width="1"/> <text x="434" y="254" class="s" style="fill:#1d4e78">p24 conical capsid</text> <line x1="264" y1="190" x2="430" y2="295" stroke="#6b7280" stroke-width="1"/> <text x="434" y="299" class="s" style="fill:#b03030">two ssRNA copies</text> <line x1="280" y1="268" x2="430" y2="340" stroke="#6b7280" stroke-width="1"/> <text x="434" y="344" class="s" style="fill:#7c3aed">reverse transcriptase,</text> <text x="434" y="360" class="s" style="fill:#7c3aed">integrase, protease, RNase H</text> <text x="320" y="408" class="s c">envelope (gp120/gp41) → p17 matrix → p24 capsid → RNA core with enzymes</text> </svg> `` Serologically, HIV RNA appears at 10–14 days; p24 antigen at 15–20 days; antibody by ELISA at 3–12 weeks (window period), shortened to about 2–4 weeks by 4th-generation p24/antibody assays; in India, NACO confirms infection by a three-test strategy using assays based on different antigens or principles (Western blot is now rarely used); CD4 count falls progressively. AIDS is diagnosed when CD4 <200 cells/µL or an AIDS-defining illness appears. Diseases include TB, PCP, cryptococcal meningitis, Kaposi sarcoma, CMV retinitis, toxoplasmosis, MAC, candidiasis, histoplasmosis, non-Hodgkin lymphoma, HIV encephalopathy, wasting and invasive cervical cancer.
(b)(i) Virtual autopsy. Virtual autopsy (virtopsy) is a non-invasive or minimally invasive post-mortem examination using post-mortem CT (PMCT), PMCT angiography, post-mortem MRI, 3D surface scanning and image-guided needle biopsy, with 3D reconstruction and virtual dissection. In India, AIIMS New Delhi started it with ICMR support. Methodology includes imaging, radiological interpretation, comparison with antemortem records and, where needed, targeted correlation. It documents internal injuries without opening the body. Merits: preserves the body, is rapid in mass disasters, useful in trauma and religious objections, though histopathology is limited.
(b)(ii) Brain death. Brain death is irreversible loss of all brain and brainstem function. After excluding reversible causes (drugs, hypothermia, metabolic disturbance), it is shown by deep coma, absent brainstem reflexes and a positive apnoea test, repeated after an interval; EEG or angiography may confirm it. Medicolegally, under the Transplantation of Human Organs Act, 1994, in India, as amended in 2011, formal certification by a Board of four medical experts is mandatory for legal death, consent and organ retrieval. It must be distinguished from coma and the persistent vegetative state, in which brainstem function persists. It permits withdrawal of life support, issuance of a legal death certificate and organ retrieval.
(c)(i) Infliximab. Infliximab is a chimeric anti-TNF-α monoclonal antibody; it neutralises soluble and membrane-bound TNF-α, suppressing macrophage/T-cell activation and granulomatous inflammation, hence immunosuppressant. It is used in moderate-severe Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriasis; risks include TB reactivation (screen before use), serious infections, infusion reactions, anti-drug antibodies, worsening heart failure, demyelination and hepatosplenic T-cell lymphoma.
(c)(ii) Natriuretic peptides. ANP is atrial, BNP ventricular and CNP endothelial; they activate GC-A/GC-B receptors, raise cGMP, causing vasodilation, natriuresis and diuresis and inhibiting the RAAS. They are degraded by neprilysin, and neprilysin inhibition with sacubitril (combined with valsartan) is now a key heart-failure therapy. Clinically, BNP >400 pg/mL or NT-proBNP >450 (<50 y), >900 (50–75 y) or >1800 (>75 y) pg/mL rules in acute heart failure; they guide prognosis and nesiritide is used in acute decompensated heart failure.
How this answer will be evaluated
Framework: Medical Science, Paper 1
What earns full marks: Comprehensive, accurate, and well-structured with all required elements and diagrams.
Evaluation rubric
Each sub-part is marked on its own, against the marks and word limit printed on the paper.
- (a)(i) (a)(i) Enteric fever: causative agents; week-wise presentation and tests. 10 marks
explain— definition/context → points in order → small example → short close
Must cover
- S. Typhi and S. Paratyphi A, B, C; faeco-oral
- Week 1: step-ladder fever, relative bradycardia; blood culture (best early), bone marrow culture
- Week 2: rose spots, splenomegaly, typhoid state; Widal rising titres; stool culture
- Week 3–4: complications (haemorrhage, perforation); stool/urine culture; recovery or carrier state
Loses marks
- Widal as first-week test
Earns more
- Rapid tests (Typhidot) limitations
Extra mark
- Antimicrobial resistance/XDR typhoid
- (a)(ii) (a)(ii) HIV virion diagram; serological pattern over time; AIDS-associated diseases. 10 marks
describe— define → structure or process in order → labelled diagram → significance
Must cover
- Labelled virion: gp120, gp41, p17 matrix, p24 capsid, two ssRNA, RT, integrase, protease
- Timeline: HIV RNA (~10 days), p24 (~2–3 weeks), antibodies (3–12 weeks; window period), 4th-gen assays
- Confirmation per NACO three-test strategy; CD4 decline; AIDS at CD4 < 200 or defining illness
- Associated diseases: TB, PCP, cryptococcal meningitis, toxoplasmosis, CMV, MAC, Kaposi, NHL, candidiasis, HIV encephalopathy, wasting
Loses marks
- No diagram
Earns more
- Graph of markers over time
Extra mark
- Seroconversion illness
- (b)(i) (b)(i) Virtual autopsy: definition, methodology, merits. 10 marks
explain— definition/context → points in order → small example → short close
Must cover
- Definition: imaging-based (virtopsy) non-invasive/minimally invasive autopsy
- Methods: PMCT, PMCT angiography, PMMR, 3D surface scanning, image-guided biopsy
- Merits: preserves body, rapid, digital record, useful in mass disasters, religious objections, trauma/gas embolism
- Limitations: histology, infections, cost; Indian experience (AIIMS)
Loses marks
- Treating it as a replacement in all cases
Earns more
- Comparison with conventional autopsy
Extra mark
- Admissibility as evidence
- (b)(ii) (b)(ii) Brain death: definition and medicolegal importance. 10 marks
define— precise definition → the distinguishing feature → one example
Must cover
- Irreversible cessation of all brain including brainstem function
- Criteria: coma, absent brainstem reflexes, apnoea test; exclusion of reversible causes; repeat testing
- THOA 1994 (amended 2011): certification by a board of four doctors
- Medicolegal: legal death, withdrawal of support, organ donation, time of death
Loses marks
- Confusing with cardiac death
Earns more
- Distinction from vegetative state
Extra mark
- THOTA 2014 rules
- (c)(i) (c)(i) Why infliximab is an immunosuppressant; therapeutic uses. 5 marks
discuss— intro → 3-4 dimensions → example → balanced close
Must cover
- Chimeric anti-TNF-α monoclonal antibody
- Neutralises soluble/membrane TNF; reduces cytokine cascades, granuloma maintenance
- Uses: Crohn's, UC, RA, ankylosing spondylitis, psoriasis/psoriatic arthritis
- Risks: TB reactivation (screen), serious infections, infusion reactions, anti-drug antibodies
Loses marks
- Calling it a TNF agonist
Earns more
- Combination with methotrexate
Extra mark
- Biosimilars
- (c)(ii) (c)(ii) Natriuretic peptides: pharmacology and clinical uses. 5 marks
describe— define → structure or process in order → labelled diagram → significance
Must cover
- ANP (atria), BNP (ventricles), CNP (endothelium)
- NPR-A/B → cGMP: natriuresis, vasodilatation, RAAS inhibition; degraded by neprilysin
- Diagnostic use of BNP/NT-proBNP in heart failure
- Therapeutic: nesiritide (recombinant BNP), sacubitril/valsartan (neprilysin inhibition)
Loses marks
- No clinical use
Earns more
- Cut-off values
Extra mark
- Carperitide
What "Describe" is asking you to do
Give a full, ordered account of the thing named — its parts, stages or mechanism — in the sequence in which it actually exists or occurs. Most describe questions come from the science optionals, where the marks sit in correct technical detail and, where the stem says so, a labelled diagram.
Structure that answers it
One-line identification of the subject → the parts or stages in their real order, each with its defining detail → labelled diagram where the subject is structural → closing line on function or significance
Where marks are lost
Loose general prose where the examiner is ticking named parts, correct terminology and their sequence; and in the General Studies papers, turning to evaluation before the description is finished.
Practice this exact question
Write your answer and it is marked point by point against the model answer above — what you covered, what you missed, what you got wrong.
Evaluate my answer →More from Medical Science 2024 Paper I
- Q5 Discuss the antiviral spectrum and therapeutic uses of acyclovir. Doxorubicin is an antib…
- Q6 Describe the microscopic features of breast cancer. Enumerate any five major prognostic f…
- Q7 Define death due to hanging. What are the probable causes of death in hanging? What are t…
- Q8 What is enteric fever? What are its causative agents? Give a detailed presentation of a c…